id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-012795-6m88m81v	Yu, Hai-jun	Nanomedicine and cancer immunotherapy	2020-05-28		.txt	text/plain	1839	90	30	The prime aim for the special issue is to deliver both high-impact review and research articles to the wide international readership regarding the most recent progress in nano-immunotherapy as well as the approaches for enhancing the efficacy of cancer immunotherapy. To increase cancer immunotherapies' impact, we organized this special issue to deepen our understanding about the mechanisms underlying the tumor and immune cells to evade immunity, how nanomedicines can be used to reprogram the tumor microenvironment and how nanomedicines interact with the immune system, and the potential challenges and the critical limitations of immunotherapy approaches, which impede their clinical applications. However, ICD-based immunotherapy is restricted by the ITM limiting its efficacy in eliciting a long-term anti-tumor immune response as well as severe systemic toxicity. To address these challenges, nanomedicine-based drug delivery strategies have been exploited to improve cancer immunotherapy by boosting ICD of tumor cells.	./cache/cord-012795-6m88m81v.txt	./txt/cord-012795-6m88m81v.txt